GSK Says Will 'Sit Out' Current Big M&A Frenzy
This article was originally published in Scrip
GlaxoSmithKline PLC says it will not join the current melee of big M&A sweeping the sector but will instead concentrate on 'bedding down' its constituent parts after its transformational asset swap with Swiss rival Novartis AG, completed last year.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.